Melatonin-Based Therapeutics for Atherosclerotic Lesions and Beyond: Focusing on Macrophage Mitophagy
Amir Ajoolabady1,2, David J. McClements3, Yaguang Bi2, Gregory Y.H Lip4, Des R. Richardson5,6,7, Daniel J. Klionsky8*, Russel J. Reiter9*, and Jun Ren2,10*
1Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA; 2Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China; 3Department of Food Science, University of Massachusetts Amherst, Amherst, MA, 01003, USA;4University of Liverpool Institute of Ageing and Chronic Disease, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom of Great Britain and Northern Ireland;5Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales 2006, Australia; 6Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; 7Centre for Cancer Cell Biology and Drug Discovery, Griffith Institute for Drug Discovery, Griffith University, Nathan, Brisbane, Queensland 4111, Australia; 8Life Sciences Institute and Departments of Molecular, Cellular and Developmental Biology and Biological Chemistry, University of Michigan, Ann Arbor 48109, USA;9Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX, USA;10Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, 98195 USA